Kepos Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Kepos Capital’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-9,944	Closed	-$563K	–	430
2019 Q3	$563K	Hold	9,944	–	–	0.06%	184
2019 Q2	$554K	Hold	9,944	–	–	0.06%	214
2019 Q1	$502K	Hold	9,944	–	–	0.04%	281
2018 Q4	$401K	Hold	9,944	–	–	0.03%	294
2018 Q3	$689K	Hold	9,944	–	–	0.04%	266
2018 Q2	$752K	Hold	9,944	–	–	0.04%	240
2018 Q1	$524K	Hold	9,944	–	–	0.03%	219
2017 Q4	$531K	Buy	+9,944	New	+$553K	0.05%	163

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Kepos Capital's EGRX Position: Q4 2019 in Review

Kepos Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2019, closing a stake of 9,944 shares — an estimated $563K sold.

Kepos Capital first reported a position in EGRX in Q4 2017 and held it in 8 quarters. The position peaked at $752K in Q2 2018. 176 funds tracked by Wall St. Rank hold EGRX as of Q4 2019.

Kepos Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Kepos Capital sold 9,944 Eagle Pharmaceuticals, Inc. shares in Q4 2019, an estimated $563K.
Kepos Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 8 quarters.
Kepos Capital's Eagle Pharmaceuticals, Inc. position peaked at $752K in Q2 2018.
176 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2019.

Based on Kepos Capital's 13F filing for Q4 2019, filed 13 Feb 2020.